SCHEMBL3985804

SCHEMBL3985804

O=C(O)c1c(NS(=O)(=O)c2ccccc2F)ccc2cc[nH]c12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACLY P53396 3/20 0.52
PTPRC P08575 1/20 0.51
PTPN2 P17706 1/20 0.51
PTPN1 P18031 1/20 0.51
PTPRB P23467 1/20 0.51
PTPRE P23469 1/20 0.51
PTPN6 P29350 1/20 0.51
METAP2 P50579 3/20 0.46
METAP1 P53582 1/20 0.44
PTK2B Q14289 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
TSHR P16473 1/20 0.42
KDM4E B2RXH2 2/20 0.41
KAT6A Q92794 3/20 0.41
FABP4 P15090 1/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
NR3C1 P04150 1/20 0.39
PGR P06401 1/20 0.39
NR3C2 P08235 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3984731 0.85 METAP2 (0.55) ACLYPTPRCPTPN2PTPN1PTPRB
SCHEMBL3982699 0.84 METAP2 (0.63) ACLYPTPRCPTPN2PTPN1PTPRB
SCHEMBL3988437 0.81 METAP2 (0.62) PTPRCPTPN2PTPN1PTPRBPTPRE
SCHEMBL3985482 0.80 METAP2 (0.69) ACLYMETAP2METAP1PTK2BSMN1; SMN2
SCHEMBL3982513 0.79 METAP2 (0.49) ACLYPTPRCPTPN2PTPN1PTPRB
SCHEMBL3982706 0.76 PTPRC (0.53) PTPRCPTPN2PTPN1PTPRBPTPRE
SCHEMBL3985610 0.76 PTPRC (0.53) ACLYPTPRCPTPN2PTPN1PTPRB
SCHEMBL3982247 0.74 PTPRC (0.49) PTPRCPTPN2PTPN1PTPRBPTPRE
SCHEMBL3980189 0.73 PTK2B (0.47) ACLYMETAP2METAP1PTK2BSMN1; SMN2
SCHEMBL3982737 0.73 ESR1 (0.53) PTPRCPTPN2PTPN1PTPRBPTPRE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7491718-B2 Sulfonamides having antiangiogenic and anticancer activity ABBOTT LABORATORIES (US) 2009-02-17 US disclosed
US-20040167128-A1 Sulfonamides having antiangiogenic and anticancer activity ABBVIE INC. 2004-08-26 US disclosed
US-20040157836-A1 Sulfonamides having antiangiogenic and anticancer activity ABBOTT LABORATORIES 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040167128-A1 Sulfonamides having antiangiogenic and anticancer activity METAP2, METAP1, DNPEP ACLY 2986/4885PTPRC 2454/4885PTPN2 964/4885
US-20040157836-A1 Sulfonamides having antiangiogenic and anticancer activity METAP2, METAP1, DNPEP ACLY 2986/4885PTPRC 2454/4885PTPN2 964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.